PsiThera, Inc.

PsiThera, Inc. , based in Watertown, US, specializes in developing oral small molecules aimed at immunology and inflammatory diseases, replacing traditional injected biologics with innovative therapies. Founded in 2022 and headquartered in Watertown, US, PsiThera, Inc. focuses on creating oral therapeutics targeting immunological conditions.

The company has completed 2 deals and successfully raised USD 47. 50 mn in its Series A funding round from investors including Eurofarma Ventures and Lightstone Ventures. The firm has not undergone any significant business strategy pivots or changes in operations. PsiThera specializes in the development of innovative oral small molecules targeting high-value immunology and inflammatory disease areas that have traditionally relied on injected biologics.

Central to their offerings is the QUAISAR platform, which models biologically relevant protein motion to identify hidden druggable states often overlooked by conventional drug discovery. This platform enables the design of therapeutics aimed at specific targets within the tumor necrosis factor (TNF) superfamily and other validated immunological targets. PsiThera’s product pipeline is designed to provide solutions for patients with limited options beyond injection-based treatments, serving a global market that includes North America, Europe, and parts of Asia. PsiThera's revenue model is built around partnerships and collaborations within the biopharmaceutical sector, focusing on delivering its proprietary drug candidates to pharmaceutical companies and healthcare providers.

Transactions typically occur through licensing agreements, where PsiThera grants rights to its technologies and products in exchange for upfront payments and royalties on future sales. Flagship products developed through the QUAISAR platform are expected to drive these agreements, as they aim to introduce the first oral therapies in their respective categories. The firm’s business structure emphasizes B2B relationships, targeting pharmaceutical partners rather than direct-to-consumer sales, with anticipated revenue generation further supported by milestone payments tied to the successful development and commercialization of their therapeutic candidates. PsiThera, Inc.

plans to leverage its recent Series A funding of USD 47. 50 mn to support the design and launch of new oral therapies. The company is focused on expanding its presence into new markets in Europe and Asia by 2025. The funding will enable PsiThera to enhance its QUAISAR platform and accelerate the development of innovative products tailored for regions with significant unmet medical needs.